267 related articles for article (PubMed ID: 1701660)
1. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
Stoner E
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
[TBL] [Abstract][Full Text] [Related]
2. Finasteride for benign prostatic hyperplasia.
Hasinski S; Miller JL; Rose LI
Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
[TBL] [Abstract][Full Text] [Related]
3. Finasteride: a 5 alpha-reductase inhibitor.
Steiner JF
Clin Pharm; 1993 Jan; 12(1):15-23. PubMed ID: 7679063
[TBL] [Abstract][Full Text] [Related]
4. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
5. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia.
Vermeulen A; Giagulli VA; De Schepper P; Buntinx A
Eur Urol; 1991; 20 Suppl 1():82-6. PubMed ID: 1722168
[TBL] [Abstract][Full Text] [Related]
6. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.
Geller J; Sionit L
J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893
[TBL] [Abstract][Full Text] [Related]
7. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
[TBL] [Abstract][Full Text] [Related]
8. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
9. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.
Guess HA; Heyse JF; Gormley GJ
Prostate; 1993; 22(1):31-7. PubMed ID: 7678930
[TBL] [Abstract][Full Text] [Related]
10. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
Imperato-McGinley J; Shackleton C; Orlic S; Stoner E
J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
[TBL] [Abstract][Full Text] [Related]
11. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group.
Stoner E
J Urol; 1992 May; 147(5):1298-302. PubMed ID: 1373779
[TBL] [Abstract][Full Text] [Related]
12. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.
Tempany CM; Partin AW; Zerhouni EA; Zinreich SJ; Walsh PC
Prostate; 1993; 22(1):39-42. PubMed ID: 7678931
[TBL] [Abstract][Full Text] [Related]
13. Finasteride: the first 5 alpha-reductase inhibitor.
Sudduth SL; Koronkowski MJ
Pharmacotherapy; 1993; 13(4):309-25; discussion 325-9. PubMed ID: 7689728
[TBL] [Abstract][Full Text] [Related]
14. 5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review.
Imperato-McGinley J
Eur Urol; 1991; 20 Suppl 1():78-81. PubMed ID: 1722167
[TBL] [Abstract][Full Text] [Related]
15. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
16. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
Kirby RS; Vale J; Bryan J; Holmes K; Webb JA
Eur Urol; 1993; 24(1):20-6. PubMed ID: 7689971
[TBL] [Abstract][Full Text] [Related]
17. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
18. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
20. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
